Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Mdwd save search
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 5.63%
H: 4.97%
C: -0.88%
escharex positive results study
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -0.15%
H: 4.18%
C: 2.36%
nexobrid chmp approval positive treat
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
Published: 2023-09-28 (Crawled : 13:00) - globenewswire.com
VCEL | $43.74 -0.27% -0.27% 520K
|
Health Technology
|
| O: 0.73%
H: 0.59%
C: -4.72%
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 0.33%
H: 19.07%
C: 17.77%
nexobrid positive publication results study
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
Published: 2023-07-10 (Crawled : 12:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -0.67%
H: 5.36%
C: 0.96%
mw005 positive cell treatment results study
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
Published: 2023-07-03 (Crawled : 11:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 1.13%
H: 3.9%
C: 1.39%
positive escharex study
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 6.21%
H: 0.99%
C: -12.99%
mw005 treatment positive study cell carcinoma
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Published: 2022-05-12 (Crawled : 11:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 3.33%
H: 3.23%
C: 2.69%
trial positive phase 2
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -1.57%
H: 5.6%
C: 0.4%
phase 2 trial topline results positive topline
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -0.82%
H: 1.24%
C: -2.89%
phase 2 positive
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -0.98%
H: 3.45%
C: -0.99%
phase 2 positive designation
MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
Published: 2021-07-20 (Crawled : 12:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 10.17%
H: 0.07%
C: -11.05%
positive results topline phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.